Fulltext

Evaluation of commercially available tests for Chlamydia nucleic acid detection in synovial fluid of patients

Bas, S. ; Ninet, B. ; Delaspre, O. ; Vischer, T L.

In: British journal of rheumatology, 1997, vol. 36, no. 2, p. 198-202

Aggiungi alla tua lista
    Titre
    • Evaluation of commercially available tests for Chlamydia nucleic acid detection in synovial fluid of patients
    Auteur
    • Bas, S.. Division of Rheumatology, University Hospital, Geneva, Switzerland.
    • Ninet, B.. Division of Rheumatology, University Hospital, Geneva, Switzerland.
    • Delaspre, O.. Division of Rheumatology, University Hospital, Geneva, Switzerland.
    • Vischer, T L.. Division of Rheumatology, University Hospital, Geneva, Switzerland.
    Type de document
    • Postprint
    Identifiant OAI-PMH
    • oai:doc.rero.ch:290004
    Summary
    Since the presence of Chlamydia nucleic acids has been shown in synovial fluid (SF) from some patients with Chlamydia reactive arthritis, we investigated whether commercially available tests, developed to detect Chlamydia nucleic acids in urogenital samples, could also be used for their detection in SF samples. We therefore tested SF samples, found positive with at least two different systems of DNA amplification in a previous study, with three commercially available kits. No positive results were obtained. It is concluded that the commercially available tests Gen-Probe PACE 2, Amplicor (developed by Roche Molecular Systems) and LCx (developed by Abbott Laboratories) do not have sufficient sensitivity to detect reliably Chlamydia RNA or DNA in SF